The US Food and Drug Administration is hosting a one-day virtual public workshop called “Increasing the Efficiency of Biosimilar Development Programs” on September 19 from 9 a.m. to 4 p.m.
FDA
Symposium on AI in Clinical Drug Development Provides Forum to Discuss Policy
The symposium brought together participants from the FDA, pharmaceutical industry, and major academic institutions to discuss policy implications of implementing artificial intelligence in clinical drug development.
BASS XXIX Heads to NC in October
Tutorials on topics pertinent to the research, clinical development, and regulation of pharmaceuticals will be presented by speakers from academia, the industry, and the FDA.
2023 ASA Board of Directors Candidates
The ASA announces the candidates for the 2022 election. Voting begins April 11 and runs through May 2. Make sure to look for your ballots in your email inbox.
Increasing JEDI in Clinical Trials
During the ASA Biopharmaceutical Section Regulatory-Industry Statistics Workshop this past September, Godwin Yung and Dooti Roy held a roundtable discussion on increasing Justice, Equity, Diversity, and Inclusion (JEDI) in clinical trials. Here, they share three takeaways from the conversation.
People News for March 2022
See what ASA members have been up to in March 2022’s People News.
Therri Usher
Therri Usher always enjoyed mathematics, even competing in competitions during high school. Despite this, others encouraged her to pursue a career as a medical doctor, so she entered college as a pre-med student. However, when she was offered the opportunity to work in a biology lab researching sickle cell disease and conducting data analysis, she changed her major to biostatistics with a specialization in statistics. After completing her PhD, Therri joined the US Food and Drug Administration, where she applies statistical theories and methods used in the regulation of drug products to treat viral infections and rare diseases.
My ASA Story: Richard Zink, Biostatistician and Podcaster
Zink is the co-host of ASA Biopharm’s Podcast and says volunteering has been good for his career and allowed him to help the next generation of statisticians and data scientists.
Ralph D’Agostino: Editor, Adviser, Researcher, Professor
Ralph D’Agostino stepped down from his role as editor of Statistics in Medicine December 31, 2019. The major areas in which he excelled include being the lead biostatistician for the Framingham Heart Study, a biostatistical consultant to The New England Journal of Medicine, a member and consultant on federal drug advisory committees, and a 52-year faculty member in mathematics and statistics at Boston University.
Meet Sylva Collins, Director of the Office of Biostatistics, US Food and Drug Administration
Sylva Collins joined the FDA’s Office of Biostatistics in 2019 and has more than 30 years of drug development experience and biostatistics leadership.







